Business Wire

The newsfeed available here is provided by our content partner Business Wire. This is one of the most important and widest-reaching press services, providing news, press releases and multimedia content to the media, journalists and the public. Business Wire is a subsidiary of the Warren Buffett Group Berkshire Hathaway.
The NewsWire Hub ("X-Billboard") currently comprises four of the most important international news sources and is supplemented by a stock market information service. The individual newswire services complement each other and provide a complementary range of information, more than three quarters of the official news sources on which editors worldwide base their stock market reporting. Your advantage: You will find everything here in one overview. You can navigate to the individual sections using the control elements. In the terminal view, you can carry out individual searches at company level.
System-State: Number of processed items 20.974 Notifications successully processed since Inception
Business Wire is an important news source that can be accessed via the X-Billboard. It is part of the Newswire Hub, which bundles important international news sources for stock market participants in one central location. If you want to get a quick overview, you can easily scroll through the headlines. If you want to look at the news in more detail, you can use the detailed views of the info cards to directly access the respective news item and other analysis tools.
NEWS
EXPLORER
US28176E1082
State: 24.12.2024 | 12AM
Do you already know our new terminal view? Click here.
FIGI: BBG000BRXP69
EW

Edwards Lifesciences Corporation
GICS: - · Sector: Healthcare · Sub-Sector: Medical Devices
NAME
Edwards Lifesciences Corporation
ISIN
US28176E1082
TICKER
EW
MIC
XNYS
REUTERS
EW.N
BLOOMBERG
EW US
Thu, 12.12.2024       Edwards Lifesciences

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Edwards Lifesciences Corporation (“Edwards” or the “Company”) (NYSE: EW) and reminds investors of the December 13, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company....
Thu, 12.12.2024       Edwards Lifesciences

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 13, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Edwards Lifesciences Corporation (“Edwards Lifesciences” or the “Company”) (NYSE: EW) securities between February 6, 2024 and July 24, 2024, inclusive (the “Clas...
Wed, 11.12.2024       Edwards Lifesciences

Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of securities of Edwards Lifesciences Corporation (NYSE: EW) between February 6, 2024 and July 24, 2024. Edwards describes itself as an “international company that researches, develops, provides products and tech...
Wed, 04.12.2024       Edwards Lifesciences

Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s focused strategy for long-term sustainable growth, provide an update on its technology pipeline to serve more patients and share financial guidance today during its annual investor conference. Edwards enters 2025, its first full year as a purely structural heart company, in a s...
Tue, 03.12.2024       Edwards Lifesciences

The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Edwards Lifesciences Corporation (“Edwards”) (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the “Class...
Mon, 25.11.2024       Edwards Lifesciences

Edwards Lifesciences (NYSE: EW) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented at PCR London Valves 2024 and simultaneously published in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions. An analysis of data from mo...
Wed, 30.10.2024       Edwards Lifesciences

Edwards Lifesciences (NYSE: EW) today announced significant additions to the body of high-quality evidence presented and published during the Transcatheter Cardiovascular Therapeutics (TCT) conference, addressing the critical needs of patients with structural heart disease. “The data at TCT on Edwards’ innovations underscore our commitment to sci...
Wed, 30.10.2024       Edwards Lifesciences

Edwards Lifesciences Corporation (NYSE: EW) today announced that the EVOQUE system demonstrated superiority compared to medical therapy alone for the one-year primary endpoint of the TRISCEND II trial. TRISCEND II is a randomized controlled pivotal trial designed to study the groundbreaking EVOQUE transcatheter tricuspid valve replacement (TTVR) s...
Mon, 28.10.2024       Edwards Lifesciences

Edwards Lifesciences (NYSE: EW) today announced results from the EARLY TAVR Trial, the first randomized, controlled trial designed to study the best strategy for treating asymptomatic severe aortic stenosis (AS) and the benefits of early intervention with transcatheter aortic valve replacement (TAVR). The trial results demonstrated that asymptomat...
Sun, 27.10.2024       Edwards Lifesciences

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Edwards Lifesciences Corporation (“Edwards” or “the Company”) (NYSE: EW) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for a...
Thu, 24.10.2024       Edwards Lifesciences

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Sept. 30, 2024. Highlights and Outlook Q3 sales from continuing operations grew 9%; constant currency1 sales grew 10% Q3 TAVR sales grew 6%; constant currency1 sales grew 7% TMTT sales grew 73%; PASCAL and EVOQUE commercial launches continue to progress w...
Wed, 23.10.2024       Edwards Lifesciences

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming December 13, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Edwards Lifesciences Corporation (“Edwards Lifesciences” or the “Company”) (NYSE: EW) securities between February 6, 2024 and July ...
Wed, 23.10.2024       Edwards Lifesciences

Law Offices of Howard G. Smith reminds investors of the upcoming December 13, 2024 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Edwards Lifesciences Corporation (“Edwards Lifesciences” or the “Company”) (NYSE: EW) securities between February 6, 2024 and July 24, 2024, inclusive (the “Class Period”...
Mon, 21.10.2024       Edwards Lifesciences

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Edwards Lifesciences Corporation (“Edwards Lifesciences” or the “Company”) (NYSE: EW) securities between February 6, 2024 and July 24, 2024, inclusive (the “Class Period”). Edwards Lifescience...
Mon, 21.10.2024       Edwards Lifesciences

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Edwards Lifesciences Corporation (NYSE: EW) securities between February 6, 2024 and July 24, 2024, both dates inclusive (the “Class Period”), have until December 13, 2024 to seek appointment as lead plaintiff of the Edwards Lifesciences class action laws...
Fri, 18.10.2024       Edwards Lifesciences

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Edwards Lifesciences Corporation (“Edwards Lifesciences” or the “Company”) (NYSE: EW) securities between February 6, 2024 and July 24, 2024, inclusi...
Fri, 18.10.2024       Edwards Lifesciences

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Edwards Lifesciences Corporation (“Edwards Lifesciences” or the “Company”) (NYSE: EW) securities between February 6, 2024 and July 24, 2024, inclusive (the “Class Period”). Edwards Lifesciences Corporation investors have until D...
Fri, 18.10.2024       Edwards Lifesciences

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Edwards Lifesciences Corporation (“Edwards” or “the Company”) (NYSE: EW) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for a...
Thu, 17.10.2024       Edwards Lifesciences

Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2024 after the market closes on Thursday, October 24, 2024, and will host a conference call at 5:30 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also ...
Thu, 17.10.2024       Edwards Lifesciences

The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Edwards Lifesciences Corporation (“Edwards”) (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the “Class...

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire crosslink panel in the upper area allows you to quickly and conveniently access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted research.


On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.